Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer cell growth: A possible radioimmunotherapy to prostate carcinoma

References

• Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW. 1999. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Research 59:4761–4764.
   PubMed Web of Science ®Google Scholar
• Ahmad I, Patel R, Singh LB, Nixon C, Seywright M, Barnetson RJ, Brunton VG, Muller WJ, Edwards J, Sansom OJ, Leung HY. 2011. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proceedings of the National Academy of Sciences of the USA 108:16392–16397.
   Google Scholar
• Albanell J, Codony J, Rovira A, Mellado B, Gascon P. 2003. Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Advances in Experimental Medicine and Biology 532:253–268.
   PubMed Web of Science ®Google Scholar
• Bolin C, Boudra MT, Fernet M, Vaslin L, Pennaneach V, Zaremba T, Biard D, Cordelieres FP, Favaudon V, Megnin-Chanet F, Hall J. 2012. The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation. Cellular and Molecular Life Sciences 69:951–962.
   Google Scholar
• Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, Gregory CW, Lin Y, Whang YE, Earp HS, Mohler JL. 2003. Human epidermal receptor-2 expression in prostate cancer. Clinical Cancer Research 9:1087–1097.
   PubMed Web of Science ®Google Scholar
• Chen KT, Lee TW, Lo JM. 2009. In vivo examination of (188)Re(I)- tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer. Nuclear Medicine and Biology 36:355–361.
   Google Scholar
• Demelash A, Rudrabhatla P, Pant HC, Wang X, Amin ND, McWhite CD, Naizhen X, Linnoila RI. 2012. Achaete-Scute Homolog-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway. Molecular Biology of the Cell 23:2856–2866.
   Google Scholar
• Dhavan R, Tsai LH. 2001. A decade of CDK5. Nature Reviews Molecular Cell Biology 2:749–759.
   PubMed Web of Science ®Google Scholar
• Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI. 1994. The neu-oncogene: Signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9:2109–2123.
   PubMed Web of Science ®Google Scholar
• Eggers JP, Grandgenett PM, Collisson EC, Lewallen ME, Tremayne J, Singh PK, Swanson BJ, Andersen JM, Caffrey TC, High RR, Ouellette M, Hollingsworth MA. 2011. Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. Clinical Cancer Research 17:6140–6150.
   PubMed Web of Science ®Google Scholar
• Formento P, Hannoun-Levi JM, Gerard F, Mazeau C, Fischel JL, Etienne-Grimaldi MC, Gugenheim J, Milano G. 2005. Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft. European Journal of Cancer 41:1467–1473.
   PubMed Web of Science ®Google Scholar
• Henry RY, O’Mahony D. 1999. Treatment of prostate cancer. Journal of Clinical Pharmacy and Therapeutics 24:93–102.
   Google Scholar
• Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM. 2004. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. British Journal of Cancer 90:449–454.
   PubMed Web of Science ®Google Scholar
• Hsu FN, Yang MS, Lin E, Tseng CF, Lin H. 2011a. The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells. American Journal of Physiology, Endocrinology and Metabolism 300:E902–908.
   Google Scholar
• Hsu FN, Chen MC, Chiang MC, Lin E, Lee YT, Huang PH, Lee GS, Lin H. 2011b. Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5. Journal of Biological Chemistry 286:33141–33149.
   Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics, 2007. CA:A Cancer Journal for Clinicians 57:43–66.
   Google Scholar
• Lee KY, Rosales JL, Tang D, Wang JH. 1996. Interaction of cyclin- dependent kinase 5 (Cdk5) and neuronal Cdk5 activator in bovine brain. Journal of Biological Chemistry 271:1538–1543.
   Google Scholar
• Legrier ME, Oudard S, Judde JG, Guyader C, de Pinieux G, Boye K, de Cremoux P, Dutrillaux B, Poupon MF. 2007. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. British Journal of Cancer 96:269–276.
   Google Scholar
• Lin H, Juang JL, Wang PS. 2004. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. Journal of Biological Chemistry 279:29302–29307.
   PubMed Web of Science ®Google Scholar
• Lin H, Lin TY, Juang JL. 2007a. Abl deregulates Cdk5 kinase activity and subcellular localization in Drosophila neurodegeneration. Cell Death and Differentiation 14:607–615.
   PubMed Web of Science ®Google Scholar
• Lin H, Chen MC, Chiu CY, Song YM, Lin SY. 2007b. Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells. Journal of Biological Chemistry 282:2776–2784.
   Google Scholar
• Luo TY, Tang IC, Wu YL, Hsu KL, Liu SW, Kung HC, Lai PS, Lin WJ. 2009. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment. Nuclear Medicine and Biology 36:81–88.
   Google Scholar
• Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. 2004. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6:517–527.
   PubMed Web of Science ®Google Scholar
• Meyn RE. 1997. Apoptosis and response to radiation: Implications for radiation therapy. Oncology (Williston Park) 11:349–356; discussion 356,361,365.
   PubMedGoogle Scholar
• Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. 2002. HER-2 profiling and targeting in prostate carcinoma. Cancer 94:980–986.
   PubMed Web of Science ®Google Scholar
• Neve RM, Lane HA, Hynes NE. 2001. The role of overexpressed HER2 in transformation. Annals of Oncology 12:S9–13.
   PubMedGoogle Scholar
• Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C. 2001. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clinical Cancer Research 7:2643–2647.
   PubMed Web of Science ®Google Scholar
• Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. 1999. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615–622.
   PubMed Web of Science ®Google Scholar
• Rasaneh S, Rajabi H, Babaei MH, Daha FJ. 2010. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nuclear Medicine and Biology 37:949–955.
   PubMed Web of Science ®Google Scholar
• Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, Spada D, Boninsegna A, Valentini V, Cittadini A. 2004. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 (‘Iressa’) induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. Journal of Cellular Physiology 201: 97–105.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Goldenberg DM. 2011. Cancer radioimmunotherapy. Immunotherapy 3:349–370.
   PubMed Web of Science ®Google Scholar
• Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJ. 2001. Her-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease. Journal of Urology 166:1514–1519.
   PubMedGoogle Scholar
• Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M. 2000. Her-2-neu expression and progression toward androgen independence in human prostate cancer. Journal of the National Cancer Institute 92:1918–1925.
   PubMed Web of Science ®Google Scholar
• Stavridi F, Karapanagiotou EM, Syrigos KN. 2010. Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treatment Reviews 36:122–130.
   PubMed Web of Science ®Google Scholar
• Stephens LC, Ang KK, Schultheiss TE, Milas L, Meyn RE. 1991. Apoptosis in irradiated murine tumors. Radiation Research 127:308–316.
   PubMed Web of Science ®Google Scholar
• Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD. 2006. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Research 66:7509–7515.
   Google Scholar
• Telliez A, Desroses M, Pommery N, Briand O, Farce A, Laconde G, Lemoine A, Depreux P, Henichart JP. 2007. Derivatives of Iressa, a specific epidermal growth factor receptor inhibitor, are powerful apoptosis inducers in PC3 prostatic cancer cells. ChemMedChem 2:318–332.
   PubMed Web of Science ®Google Scholar
• Tsai LH, Delalle I, Caviness VS Jr, Chae T, Harlow E. 1994.p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371:419–423.
   PubMed Web of Science ®Google Scholar
• Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED. 2004. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60:332–337.
   PubMed Web of Science ®Google Scholar